@WendeHutton

General Partner, Canaan Partners Health Care Venture Capital

 Menlo Park
canaan.com
Joined May 2012
  • Tweets803
  • Following220
  • Followers1.5K
5Media
Big Pharma has a model to make a profit and save lives. So, whats the hold-up? - Blog - Business in Global Society - Harvard Business School hbs.edu/bigs/blog/post/big-p…

Big Pharma has a Model to Make a Profit and Save Lives. So, What’s the Holdup? | Institute for...

A business model developed at Harvard Business School and applied in the real world proves that Big Pharma can simultaneously earn additional profits and expand access to lifesaving drugs, if firms...

hbs.edu
6
462
CEO @CliffordStocks and CMO Bob Lechleider enjoying their time in Chicago at the @ASCO annual meeting! #ASCO23 #EliteCancerResponders
2
1
4
493
AACR 2023 has begun! OncoResponse has a poster presentation on April 19th, which will publicly introduce for the first time preclinical data regarding our dual-targeting antibodies for LILRB1 and LILRB2. The poster will soon be available on our website. #EliteCancerResponders
1
2
334
We are now two weeks away from presenting at #AACR2023! #OncoResponse's poster will publicly introduce for the first time our preclinical data of dual-targeting antibodies for LILRB1 and LILRB2. The poster presentation will take place April 19th. @AACR #EliteCancerResponders
1
3
349
Wende Hutton retweeted
Canaan@canaanpartners5 Apr 2023
Abyrx, Inc. announced additional FDA clearances for the company's MONTAGE® Settable, Resorbable Bone Putty as both a bone void filler and cranial bone cement, which follow the highly successful clinical introduction of MONTAGE use on bleeding bone. prnewswire.com/news-releases…

Abyrx Receives Additional FDA Clearances for MONTAGE® Settable, Resorbable Bone Putty as Bone Void...

/PRNewswire/ -- Abyrx, Inc. (http://abyrx.com), a leading biomaterial sciences company with a focus on therapeutic technologies for use during surgical...

prnewswire.com
1
590
Wende Hutton retweeted
Canaan@canaanpartners13 Dec 2022
Excited to see Qlaris Bio’s co-founder and CMO, Barbara Wirostko, on @endpts Women in Biopharma ’22 list. She is helping guide the co's effort to develop innovative therapies for debilitating ophthalmic diseases. Canaan's @WendeHutton is on co's BOD. endpts.com/special-report-20…
1
2
Wende Hutton retweeted
Canaan@canaanpartners10 Nov 2022
Big day for PACT Pharma. Data from 1st study using #CRISPR to substitute a gene in patient’s immune cells to treat cancer presented at #SITC2022 and published in @Nature. Groundbreaking research paves way for cutting-edge therapies. pactpharma.com/news/pact-pha…
1
2
Wende Hutton retweeted
Canaan@canaanpartners29 Jul 2022
Thrilled to see @HyalexOrtho appear on @BusinessInsider list of biotech startups to watch in next year. Excited to see what CEO @carl_vause and team accomplish. @WendeHutton @JuliePapanek @jesse_yeji Read full piece with BI subscription at: businessinsider.com/list-top…

Meet the 23 biotech startups that are set to take off in the next 12 months, according to top VCs

Biotech investors look at hundreds of startups each year, trying to find the best new companies. Here are the privately held, venture-backed businesses they think will take off.

businessinsider.com
2
2
Wende Hutton retweeted
Canaan@canaanpartners9 Sep 2022
Exciting to see @OncoResponse's clinical supply agreement with @Regeneron to evaluate #OR2805 in combination with Libtayo. We'll be closely watching the clinical evaluation of this combination. Canaan's @WendeHutton is on the OncoResponse board. oncoresponse.com/news-center…
1
3
Wende Hutton retweeted
Canaan@canaanpartners12 Sep 2022
IDEAYA announces positive interim data from P2 trial of darovasertib and crizotinib synthetic lethal combo. Provides rational for potential registration-enabling study in metastatic uveal melanoma. Canaan’s @TimShannonMD is chair of the IDEAYA board. media.ideayabio.com/2022-09-…

IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic...

Confirmed partial responses by RECIST observed in 4 of 8 (50% ORR) evaluable First-Line MUM patients and in 11 of 35 (31% ORR) evaluable Any-Line MUM patients Tumor shrinkage observed in 31 of 35...

media.ideayabio.com
2
2
Congrats to Julie and the Day One team! A new day for pediatric cancer patients: Day One's share price doubles on initial data for brain tumor drug fiercebiotech.com/biotech/ne…

A new day for pediatric cancer patients: Day One's share price doubles on initial data for brain...

Day One Biopharmaceuticals appears to be living up to its namesake of altering pediatric cancer care from day one, unveiling positive initial data for its brain tumor drug that saw its share p | Day...

fiercebiotech.com
1
5
Lots of people talking about a string of negative data in biopharma… yes, there have been some notable upsets
3
8
1
71
Wende Hutton retweeted
Glooko
@GlookoInc27 Apr 2022
Today, we welcome Alfonso "Chito" Zulueta to the #Glooko Board of Directors. Learn about his success at @LillyPad in the pharmaceutical industry and the experience he brings as we continue to grow as a #DigitalHealth leader: bit.ly/3Lruk24 #BetterTogether
2
2
Welcoming Chito Zulueto and his deep expertise in diabetes care to the Glooko board! glooko.com/news_reg/glooko-a…

Glooko Appoints Alfonso “Chito” Zulueta, former Eli Lilly & Company Senior Executive, to Board of...

Glooko announced the appointment of Alfonso “Chito” Zulueta, a former Eli Lilly & Company senior executive, to its Board of Directors.

glooko.com
Wende Hutton retweeted
Canaan@canaanpartners27 Apr 2022
Glooko appoints Alfonso “Chito” Zulueta, former Eli Lilly & Company Senior Executive, to Board of Directors. glooko.com/news_reg/glooko-a…

Glooko Appoints Alfonso “Chito” Zulueta, former Eli Lilly & Company Senior Executive, to Board of...

Glooko announced the appointment of Alfonso “Chito” Zulueta, a former Eli Lilly & Company senior executive, to its Board of Directors.

glooko.com
1
1
Wende Hutton retweeted
Glooko
@GlookoInc25 Apr 2022
At #ATTD2022, #Glooko will showcase its #diabetes data management and #RemotePatientMonitoring platform and industry leaders will share insights on #DigitalHealth. Experience our #ConnectedCare platform at stand 24B: bit.ly/3KKgmYW #BetterTogether
3
1
1
Wende Hutton retweeted
Canaan@canaanpartners2 Mar 2022
Rondo Therapeutics has emerged from stealth mode with a bang. $67M Series A and ambitions to tackle solid tumors with next-gen #immunooncology platform. Round led by Canaan (@nkjellson) and Red Tree VC (Jon Edwards). PR from Rondo here: rondotx.com/news

News

Stay up to date with Rondo's business and scientific achievements.

rondotx.com
2
5
Wende Hutton retweeted
Glooko
@GlookoInc16 Mar 2022
Today, #Glooko announced the acquisition of DIABNEXT, a France-based company whose #DigitalHealth platform provides #diabetes #RemotePatientMonitoring and enhances physician-patient collaboration. Learn about Glooko XT, formerly DIABNEXT: bit.ly/3wfVPH4 #BetterTogether

Glooko Expands Diabetes Offerings in France with DIABNEXT Acquisition

5
6
Like @GlookoInc's own platform, the mobile app from acquisition target @DiabNext automatically takes in readings from continuous glucose monitors, insulin pumps and pens and other devices to help diabetes patients track daily health data. fiercebiotech.com/medtech/gl…

Glooko picks up Diabnext to launch digital diabetes management platform in France

In its second acquisition of the year so far, Glooko is forging ahead in its mission not only to bulk up its digital diabetes management offerings but also to expand their reach around the world.

fiercebiotech.com
7
3
Wende Hutton retweeted
Canaan@canaanpartners3 Feb 2022
Excited to see @synthekine initiate this study of #STK012. Important continued progress for the company, which has Canaan’s @JuliePapanek on its board.
Synthekine@synthekine3 Feb 2022
We’re proud to announce the first patient has been dosed in our Phase 1 trial with #STK012. The trial will assess STK-012, our #IL2 partial agonist, for people with solid tumors: bit.ly/3utiCyt
2
4
Load more